View Item 

Show simple item record

Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation

dc.contributor.authorJohnston, A.en_US
dc.contributor.authorArnadottir, S.en_US
dc.contributor.authorGudjonsson, Johann E.en_US
dc.contributor.authorAphale, A.en_US
dc.contributor.authorSigmarsdottir, A. A.en_US
dc.contributor.authorGunnarsson, S. I.en_US
dc.contributor.authorSteinsson, J. T.en_US
dc.contributor.authorElder, J. T.en_US
dc.contributor.authorValdimarsson, H.en_US
dc.date.accessioned2010-06-01T18:57:40Z
dc.date.available2010-06-01T18:57:40Z
dc.date.issued2008-08en_US
dc.identifier.citationJohnston, A.; Arnadottir, S.; Gudjonsson, J.E.; Aphale, A.; Sigmarsdottir, A.A.; Gunnarsson, S.I.; Steinsson, J.T.; Elder, J.T.; Valdimarsson, H. (2008). "Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation." British Journal of Dermatology 159(2): 342-350. <http://hdl.handle.net/2027.42/72152>en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72152
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18547319&dopt=citationen_US
dc.format.extent747142 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rightsJournal Compilation © 2008 British Association of Dermatologistsen_US
dc.subject.otherCytokinesen_US
dc.subject.otherLeptinen_US
dc.subject.otherObesityen_US
dc.subject.otherPsoriasisen_US
dc.subject.otherResistinen_US
dc.subject.otherUVBen_US
dc.titleObesity in psoriasis: leptin and resistin as mediators of cutaneous inflammationen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum† Department of Dermatology, University of Michigan Medical Center, Ann Arbor, MI, U.S.Aen_US
dc.contributor.affiliationother* Department of Immunology, Landspitali University Hospital, Reykjavik, Icelanden_US
dc.contributor.affiliationother† Department of Medicine, University of Iceland, Reykjavik, Icelanden_US
dc.contributor.affiliationother§ Blue Lagoon Dermatological Clinic, Grindavik, Icelanden_US
dc.contributor.affiliationother¶ Ann Arbor Veterans Affairs Health System, Ann Arbor, MI, U.S.Aen_US
dc.identifier.pmid18547319en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72152/1/j.1365-2133.2008.08655.x.pdf
dc.identifier.doi10.1111/j.1365-2133.2008.08655.xen_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceChristophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314 – 20.en_US
dc.identifier.citedreferenceGriffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258 – 62.en_US
dc.identifier.citedreferenceValdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007; 23: 563 – 7.en_US
dc.identifier.citedreferenceNair RP, Stuart PE, Nistor I et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 2006; 78: 827 – 51.en_US
dc.identifier.citedreferenceValdimarsson H, Baker BS, Jonsdottir I et al. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145 – 9.en_US
dc.identifier.citedreferenceTelfer NR, Chalmers RJ, Whale K et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 128: 39 – 42.en_US
dc.identifier.citedreferenceGudjonsson JE, Thorarinsson AM, Sigurgeirsson B et al. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003; 149: 530 – 4.en_US
dc.identifier.citedreferenceNaldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case–control study. J Invest Dermatol 2005; 125: 61 – 7.en_US
dc.identifier.citedreferenceHenseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982 – 6.en_US
dc.identifier.citedreferenceRaychaudhuri SP, Gross J. Psoriasis risk factors: role of lifestyle practices. Cutis 2000; 66: 348 – 52.en_US
dc.identifier.citedreferenceMarino MG, Carboni I, De Felice C et al. Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig 2004; 16: 753 – 8.en_US
dc.identifier.citedreferenceNeimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829 – 35.en_US
dc.identifier.citedreferenceSommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321 – 8.en_US
dc.identifier.citedreferenceRucevic I, Perl A, Barisic-Drusko V et al. The role of the low energy diet in psoriasis vulgaris treatment. Coll Antropol 2003; 27: 41 – 8.en_US
dc.identifier.citedreferenceHiga-Sansone G, Szomstein S, Soto F et al. Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg 2004; 14: 1132 – 4.en_US
dc.identifier.citedreferenceHerron MD, Hinckley M, Hoffman MS et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527 – 34.en_US
dc.identifier.citedreferenceSterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007; 157: 649 – 55.en_US
dc.identifier.citedreferenceAhima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327 – 32.en_US
dc.identifier.citedreferenceCurat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744 – 7.en_US
dc.identifier.citedreferenceKanda H, Tateya S, Tamori Y et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494 – 505.en_US
dc.identifier.citedreferenceFain JN, Madan AK, Hiler ML et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273 – 82.en_US
dc.identifier.citedreferenceBruun JM, Lihn AS, Madan AK et al. Higher production of IL-8 in visceral vs. subcutaneous adipose tissue. Implication of nonadipose cells in adipose tissue. Am J Physiol Endocrinol Metab 2004; 286: E8 – 13.en_US
dc.identifier.citedreferenceGearing AJ, Fincham NJ, Bird CR et al. Cytokines in skin lesions of psoriasis. Cytokine 1990; 2: 68 – 75.en_US
dc.identifier.citedreferenceBonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients – relationships with disease severity. Clin Exp Dermatol 1994; 19: 383 – 7.en_US
dc.identifier.citedreferenceGudjonsson JE, Johnston A, Sigmundsdottir H et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1 – 8.en_US
dc.identifier.citedreferenceMuoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002; 16: 653 – 66.en_US
dc.identifier.citedreferencePelleymounter MA, Cullen MJ, Baker MB et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540 – 3.en_US
dc.identifier.citedreferenceLord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897 – 901.en_US
dc.identifier.citedreferencePalacio A, Lopez M, Perez-Bravo F et al. Leptin levels are associated with immune response in malnourished infants. J Clin Endocrinol Metab 2002; 87: 3040 – 6.en_US
dc.identifier.citedreferenceFarooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093 – 103.en_US
dc.identifier.citedreferenceFerraroni NR, Geloneze B, Mansour E et al. Severe hypoleptinaemia associated with insulin resistance in patients with common variable immunodeficiency. Clin Endocrinol (Oxf) 2005; 63: 63 – 5.en_US
dc.identifier.citedreferenceGoldberg AC, Eliaschewitz FG, Montor WR et al. Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome. Clin Immunol 2005; 114: 147 – 53.en_US
dc.identifier.citedreferenceMatarese G, Di Giacomo A, Sanna V et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 2001; 166: 5909 – 16.en_US
dc.identifier.citedreferenceDe Rosa V, Procaccini C, Cali G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007; 26: 241 – 55.en_US
dc.identifier.citedreferenceLoffreda S, Yang SQ, Lin HZ et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57 – 65.en_US
dc.identifier.citedreferenceZarkesh-Esfahani H, Pockley G, Metcalfe RA et al. High-dose leptin activates human leukocytes via receptor expression on monocytes. J Immunol 2001; 167: 4593 – 9.en_US
dc.identifier.citedreferenceMattioli B, Straface E, Quaranta MG et al. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005; 174: 6820 – 8.en_US
dc.identifier.citedreferenceSteppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307 – 12.en_US
dc.identifier.citedreferenceNagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285: 561 – 4.en_US
dc.identifier.citedreferenceSavage DB, Sewter CP, Klenk ES et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50: 2199 – 202.en_US
dc.identifier.citedreferenceUtzschneider KM, Carr DB, Tong J et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48: 2330 – 3.en_US
dc.identifier.citedreferenceKaser S, Kaser A, Sandhofer A et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286 – 90.en_US
dc.identifier.citedreferenceBokarewa M, Nagaev I, Dahlberg L et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789 – 95.en_US
dc.identifier.citedreferencePatel L, Buckels AC, Kinghorn IJ et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472 – 6.en_US
dc.identifier.citedreferenceLehrke M, Reilly MP, Millington SC et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1: e45.en_US
dc.identifier.citedreferenceSilswal N, Singh AK, Aruna B et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005; 334: 1092 – 101.en_US
dc.identifier.citedreferenceFredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238 – 44.en_US
dc.identifier.citedreferenceCorbetta S, Angioni R, Cattaneo A et al. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006; 154: 83 – 6.en_US
dc.identifier.citedreferenceBoehncke S, Thaci D, Beschmann H et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249 – 51.en_US
dc.identifier.citedreferenceVerma S, Li SH, Wang CH et al. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation 2003; 108: 736 – 40.en_US
dc.identifier.citedreferenceMu H, Ohashi R, Yan S et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006; 70: 146 – 57.en_US
dc.identifier.citedreferenceCook PW, Mattox PA, Keeble WW et al. A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. Mol Cell Biol 1991; 11: 2547 – 57.en_US
dc.identifier.citedreferenceZheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648 – 51.en_US
dc.identifier.citedreferenceStallmeyer B, Kampfer H, Podda M et al. A novel keratinocyte mitogen: regulation of leptin and its functional receptor in skin repair. J Invest Dermatol 2001; 117: 98 – 105.en_US
dc.identifier.citedreferenceFrank S, Stallmeyer B, Kampfer H et al. Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000; 106: 501 – 9.en_US
dc.identifier.citedreferenceRennekampff HO, Hansbrough JF, Kiessig V et al. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res 2000; 93: 41 – 54.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2133.2008.08655.x.pdf
Size:
729.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.